Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.
Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.
Funding Rounds (4) - $99.5MUpdate
Current Team (5)Update
|Sep 1, 2016||Business Wire - Concert Pharmaceuticals to Present at Upcoming Investor Conferences|
|Aug 9, 2016||Business Wire - Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Company Update|
|Aug 9, 2016||ir.concertpharma.com - About Concert|
|Aug 2, 2016||Business Wire - Concert Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 9, 2016|
|Jul 8, 2016||Business Wire - PureTech Appoints Feng Zhang to Scientific Advisory Board and Expands Team and Advisory Group|
|Jul 6, 2016||Business Wire - Concert Pharmaceuticals Announces Webcast at Cantor Fitzgerald Healthcare Conference|
|May 17, 2016||Business Wire - Concert Pharmaceuticals to Present at Several Upcoming Investor Conferences|
|May 5, 2016||Business Wire - Concert Pharmaceuticals Reports First Quarter 2016 Financial Results|
99 Hayden Avenue
Lexington, Massachusetts 02421